Medical Technologies, the leader in precision insulin dosing
technology for optimized glycemic management, today announced it will be
participating in two upcoming diabetes industry events, the DiabetesMine
D-Data ExChange on June 7th, 2019 and the American Diabetes
Association’s 79th Scientific Sessions on June 7-11, 2019 in San
During the DiabetesMine D-Data ExChange, Dr. Patrick Burgess, the
inventor of Monarch’s EndoTool®
Glucose Management System, will be demonstrating the FDA-cleared,
patented software showcasing its personalized dosing recommendations for
intravenous and subcutaneous insulin therapy.
On June 9th at 12 PM PST, Dr. Burgess will also be presenting
clinical research in a poster presentation at the American Diabetes
Association’s 79th Scientific Sessions. The poster, “The Impact of Late
Glucose Checks on Hypoglycemia Incidence,” will be located at 392-P in
category 01 Complications–Hypoglycemia. Monarch will also be exhibiting
at booth #738.
“In order to deliver the best care for patients and achieve optimal
clinical and financial outcomes in the acute-care setting, we must
manage hyperglycemia and avoid hypoglycemia. To do that, advanced
algorithms focused on safety and control are necessary,” said Dr.
Burgess. “We look forward to taking part in these industry events to
showcase Monarch’s solution and clinical research and to continuing the
movement to advance inpatient glycemic management.”
About Monarch Medical Technologies
Monarch Medical Technologies is the leading provider of electronic
systems for inpatient glycemic management. Monarch’s EndoTool®
Glucose Management System offers personalized dosing recommendations for
intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared,
patented software suite, EndoTool has been chosen by more than 300
hospitals to provide unsurpassed patient-specific glycemic control
across a broad population of patients, and ultimately deliver better,
safer care. For more information, please visit monarchmedtech.com.